Neurogene Stock Price, News & Analysis

Neurogene (Nasdaq: NGNE) said company management will participate in the H.C. Wainwright Genetic Medicines Virtual Conference on Tuesday, October 14, 2025 at 7:00 a.m. ET.

Format includes a fireside chat plus investor meetings. A live webcast and a limited-time replay will be available from the Investor Relations events section on Neurogene’s website.

Neurogene (Nasdaq: NGNE) announced on October 3, 2025 that its Compensation Committee approved inducement grants of non-qualified stock options to purchase an aggregate of 9,390 shares for four new employees, effective October 1, 2025.

The grants were made under the company’s 2025 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price equals Neurogene’s closing stock price on the grant date. Vesting is over four years: 25% at the first anniversary of the vesting commencement date, then equal installments every three months over the following 36 months, subject to continued employment.

Neurogene (Nasdaq: NGNE), a clinical-stage company focused on genetic medicines for rare neurological diseases, has announced the approval of inducement grants for new employees. The Compensation Committee approved non-qualified stock options to purchase 47,040 shares of common stock for six new employees on September 3, 2025.

The grants, made under the company's 2025 Inducement Plan, will vest over four years with 25% vesting on the first anniversary and the remainder vesting quarterly over the following 36 months. The exercise price equals the closing price of Neurogene's stock on the grant date. These grants comply with Nasdaq Listing Rule 5635(c)(4) as material inducements for employment.

Neurogene (Nasdaq: NGNE) reported Q2 2025 financial results and provided updates on its NGN-401 gene therapy program for Rett syndrome. The company has completed dosing in its Phase 1/2 trial and received FDA agreement on key elements of the Embolden™ registrational trial, with trial initiation activities already underway.

Financial highlights include a strong cash position of $274.5 million, providing runway into early 2028. Q2 2025 saw a net loss of $22.0 million, with R&D expenses of $19.4 million and G&A expenses of $6.7 million. The company plans to report updated clinical efficacy and safety data from the Phase 1/2 trial in H2 2025.

Neurogene (Nasdaq: NGNE), a clinical-stage company focused on genetic medicines for rare neurological diseases, has announced inducement grants for new employees. The Compensation Committee approved non-qualified stock options to purchase 27,480 shares of common stock for seven new employees on August 6, 2025.

The stock options, granted under the company's 2025 Inducement Plan, will vest over four years with 25% vesting on the first anniversary and the remaining vesting quarterly over 36 months. The exercise price equals the closing price of Neurogene's stock on the grant date. These grants comply with Nasdaq Listing Rule 5635(c)(4) as inducement material for employment.

Neurogene (Nasdaq: NGNE), a clinical-stage company focused on genetic medicines for rare neurological diseases, has announced inducement grants for two new employees. The Compensation Committee approved non-qualified stock options to purchase 4,290 shares of common stock on July 3, 2025.

The stock options, granted under the company's 2025 Inducement Plan, will vest over a four-year period, with 25% vesting after the first year and the remainder vesting quarterly over the following 36 months. The exercise price is set at the closing price of Neurogene's stock on the grant date. These grants comply with Nasdaq Listing Rule 5635(c)(4) and serve as employment inducements.

Neurogene (NASDAQ: NGNE) has announced key details of its Embolden™ registrational trial for NGN-401, a gene therapy treatment for Rett syndrome in females aged 3 years and older. The company has received FDA written agreement on critical aspects of the trial design.

The registrational trial will be a single-arm, open-label study with a proposed enrollment of 18 participants. The primary endpoint combines improvement in Clinical Global Impression-Improvement (CGI-I) scale and gain of developmental milestone/skill, compared to baseline. The study will use the 1E15 vector genomes (vg) dose.

In the Phase 1/2 trial, 10 participants have received treatment at the 1E15 vg dose, with no evidence of HLH/hyperinflammatory syndrome. Early data from the first four participants showed promising results, with participants collectively achieving 23 developmental milestones/skills across multiple domains.

The company reports a strong financial position with $292.6 million in cash and investments as of March 31, 2025, extending their runway into early 2028. Updated clinical efficacy and safety data are expected in the second half of 2025.

Neurogene (NGNE) has granted non-qualified stock options to four new employees as part of their inducement compensation package. The Inducement Grants, approved by the Company's Board Compensation Committee on June 5, 2025, allow the purchase of 39,345 shares of common stock. The options were granted under the 2025 Inducement Plan at an exercise price equal to the closing price on the grant date. These grants will vest over four years, with 25% vesting after the first year and the remaining portions vesting quarterly over the following 36 months, contingent on continued employment.

Neurogene (NASDAQ: NGNE) presented an evidence-based monitoring and treatment algorithm at the ASGCT Annual Meeting for detecting and treating hemophagocytic lymphohistiocytosis (HLH), a rare hyperinflammatory syndrome associated with high-dose AAV gene therapy. The protocol focuses on monitoring three key indicators (the "three Fs"): elevated ferritin levels, fever, and falling blood counts.

While HLH has been linked to AAV doses exceeding 1E14 vg/kg, Neurogene's Phase 1/2 trial of NGN-401 for Rett syndrome uses a lower dose in the E13 vg/kg range, where no HLH cases have been reported. The treatment algorithm includes high-dose corticosteroids as first-line treatment and anakinra as second-line treatment.